James Streisand
Plus aucun poste en cours
Profil
James Streisand worked as Vice President-Clinical Research at Genzyme Corp.
from 1998 to 2011.
He then worked as Vice President-Clinical Development at Sanofi SA from 2011 to 2013.
Prior to that, he worked as Vice President-Clinical Development at rEVO Biologics, Inc. Dr. Streisand received his undergraduate degree from Massachusetts Institute of Technology and his doctorate degree from State University of New York at Buffalo.
Anciens postes connus de James Streisand
Sociétés | Poste | Fin |
---|---|---|
Sanofi SA | Corporate Officer/Principal | 01/06/2013 |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | 01/04/2011 |
REVO BIOLOGICS INC | Directeur Technique/Scientifique/R&D | - |
Formation de James Streisand
Massachusetts Institute of Technology | Undergraduate Degree |
State University of New York at Buffalo | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Entreprise privées | 3 |
---|---|
rEVO Biologics, Inc.
rEVO Biologics, Inc. BiotechnologyHealth Technology rEVO Biologics, Inc. engages in the development and commercialization of specialty therapeutics to address unmet medical needs in patients with rare, life-threatening conditions. Its products include ATryn, which prevents blood clots during and after surgery and childbirth for patients with hereditary antithrombin deficiency. The company was founded in February 1993 and is headquartered in Framingham, MA. | Health Technology |
Sanofi SA | Health Technology |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |